期刊
BIOMARKERS IN MEDICINE
卷 9, 期 1, 页码 35-49出版社
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.14.95
关键词
American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines; breast cancer; HER2 testing; immunohistochemistry (IHC); in situ hybridization (ISH); trastuzumab
Breast cancer treatment is dependent on accurate pathologic diagnosis. HER2 testing is now universally recommended as part of evaluation of invasive breast cancer. HER2 testing is available via various slide and non-slide based assays, and interpretation of results continues to evolve. Herein we review these testing modalities and their incorporation into the 2013 ASCO/CAP guidelines. Once accurate HER2 status has been established the proper treatment based on recent clinical trials can be instituted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据